Group 1: Company Strategy and Market Position - The company has successfully adjusted its strategy in response to the national drug centralized procurement, leading to a gradual recovery in sales of contrast agents, with a steady growth trend [1][2]. - The company aims to expand its market share by actively participating in centralized procurement while enhancing marketing efforts in non-procurement markets [3]. - The approval of Gadobutrol injection in July 2024 and its subsequent inclusion in the national centralized procurement is expected to enhance the company's market presence [2]. Group 2: Product Development and R&D Progress - The company has diversified its gadolinium-based contrast agents, now offering four MRI contrast agents, which helps meet various clinical needs and enhances market competitiveness [1][2]. - Recent approvals include Gadobutrol and other formulations, with ongoing evaluations for multiple products that target significant therapeutic areas [6][7]. - The company is focusing on integrating R&D resources and improving efficiency to support its strategic expansion in various therapeutic fields [6]. Group 3: International Market Expansion - The company achieved overseas revenue of 132.16 million yuan in 2024, marking a 15.02% increase year-on-year, with products successfully entering markets in South America, Africa, and Asia [4]. - The completion of EU GMP and Brazil ANVISA GMP certifications is expected to accelerate the internationalization of the company's contrast agents [4]. Group 4: Financial Performance and Future Outlook - The company anticipates further revenue growth from the upcoming centralized procurement of Gadobutrol and Gadobenate dimeglumine, which are expected to enhance brand influence [2][3]. - The company is also exploring opportunities in the overseas market, particularly in the EU, where several products have received registration [4]. Group 5: Subsidiary and Partner Developments - The acquisition of Tianyuan Pharmaceutical has led to successful integration into the group management system, focusing on enhancing operational efficiency across various departments [10]. - Recent advancements by partners, such as the launch of innovative cancer screening technologies by Shihe Gene, indicate a positive trend in the healthcare sector [11][12].

Financial Performance - In Q1 2025, the company achieved revenue of 282.68 million CNY, a year-on-year increase of 36.23% [1] - Net profit attributable to shareholders was 14.54 million CNY, up 26.13% year-on-year [1] - Net profit excluding non-recurring items reached 13.09 million CNY, reflecting a 14.34% increase year-on-year [1] Growth Drivers - The chemical generic drug segment capitalized on national procurement policies, expanding market share and sales [1] - The traditional Chinese medicine segment achieved rapid integration and expansion through acquisitions, enhancing product pipelines [2] - International market expansion has shown results, with continuous growth in export business [2] Market Strategy - The company aims to increase domestic market share while actively participating in procurement and promoting other products [3] - New product development and market entry will be accelerated to enhance competitiveness [3] - The company will leverage EU GMP and Brazil GMP certifications to boost international market contributions [3] Acquisition Progress - The integration of Tianyuan Pharmaceutical is progressing smoothly across production, marketing, finance, and supply chain management [4] - The company is focusing on fine management and sustainable development of Tianyuan Pharmaceutical [4] Overseas Revenue - In the reporting period, overseas revenue reached 132.16 million CNY, a year-on-year increase of 15.02% [6] - The company successfully exported contrast agents and raw materials to markets in South America, Africa, and Asia [5] R&D Developments - R&D investment for the period was 69.24 million CNY, a decrease of 43.40% year-on-year due to a stabilization phase in project initiation [7] - The company has 12 projects under review and 23 new projects initiated, totaling 35 projects [7] - Recent approvals include various formulations and specifications for contrast agents and other medications [7] Production Base Development - The construction of the Bozhou production base is progressing, with the first phase expected to begin trial production within the year [8] - The base will enhance production capacity for various dosage forms, supporting future strategic expansions in traditional and chemical medicine [8]

Group 1: Financial Performance - The company achieved a turnaround in 2024, primarily due to product structure optimization and increased marketing efforts, leading to stable revenue growth in the chemical drug sector [1] - The acquisition of 80% of Tianyuan Pharmaceutical contributed to revenue growth in the traditional Chinese medicine segment [1] - The company managed to reduce R&D investment compared to 2023 while maintaining a high level of overall R&D input [1][2] Group 2: R&D Strategy - In 2025, the R&D focus will be on chemical drugs, traditional Chinese medicine, and the health sector, aiming for technological innovation and market expansion [3] - The company received approval for "Silicone Oil Emulsion" and "Compound Polyethylene Glycol Electrolyte Powder (III)" in February 2025, enhancing its product pipeline in the digestive system field [3] - A strategic partnership with Anhui Chengqing Tang National Medicine Co., Ltd. aims to modernize traditional Chinese medicine production [3] Group 3: Subsidiary Operations - Shenzhen Yiwei Medical Technology Co., Ltd., a subsidiary, specializes in early screening, precise diagnosis, and rehabilitation for brain diseases, recognized as a national "little giant" enterprise [4] - Yiwei Medical's core products address stroke, Alzheimer's disease, cognitive disorders, and developmental disabilities, providing comprehensive solutions in the brain disease sector [5] Group 4: Business Model - Yiwei Medical offers a full-service model from screening to rehabilitation, creating a closed-loop medical service system [6] - The company collaborates with health check institutions to provide a comprehensive "brain routine" health check package [6] Group 5: International Expansion - The company has made significant progress in overseas markets, achieving full product line sales of contrast agents and obtaining EU GMP and Brazil ANVISA GMP certifications for its production line [7][8] - The company is accelerating the registration of contrast agent products for international markets, laying the groundwork for broader market expansion [8] Group 6: Acquisition Strategy - Recent acquisitions, such as Haichang Pharmaceutical and Tianyuan Pharmaceutical, have strengthened the company's competitive position in the contrast agent and traditional Chinese medicine markets [9] - Future acquisitions will align with the company's overall strategic development and business growth needs, adhering to regulatory requirements [9]

Group 1: Company Performance - The company achieved profitability in 2024, driven by product structure optimization and increased marketing efforts, leading to stable revenue growth in the chemical drug sector [1] - The acquisition of 80% of Tianyuan Pharmaceutical contributed to revenue growth in the traditional Chinese medicine segment [1] - R&D investment remained high but decreased compared to 2023, with no goodwill impairment recorded in the current reporting period [1] Group 2: Marketing Strategies - The marketing strategy for Jiuwu Zhenxin Granules will be adjusted following the change in the National Medical Insurance Drug List, which now limits its use to "generalized anxiety disorder with heart and spleen deficiency" [2] - The company is developing a series of health products targeting sleep disorders in young and elderly populations, currently under review for approval [2] Group 3: Subsidiary Developments - Shenzhen Yiwei Medical Technology Co., Ltd. is recognized as a national-level "little giant" enterprise, focusing on early screening and treatment of brain diseases with AI technology [3] - Yiwei Medical's core products include AI software for early Alzheimer's diagnosis and a comprehensive stroke diagnosis platform, both of which have received multiple certifications [4][5] Group 4: Gene Technology Progress - Shihe Gene achieved profitability in 2023 and is progressing towards an IPO, with a focus on automated NGS solutions for clinical applications [6] - The company has received FDA breakthrough device designation for its multi-cancer early screening product and is expanding its global presence [6][7] Group 5: International Market Expansion - The company has successfully achieved overseas sales for its entire line of contrast agents and has received EU GMP and Brazil ANVISA GMP certifications for its production facilities [8][9] - Ongoing efforts to expedite the registration of contrast agent products for international markets are underway, enhancing the company's global business channels [9]